The role of semaglutide in the treatment of type 2 diabetes mellitus in a female patient with sarcopenia: A clinical case
E.V. Uzhakova
Abstract. Current article considers a clinical case describing the influence of combination therapy, including long-acting insulin, semaglutide, and metformin, on the course of sarcopenia and key parameters of carbohydrate metabolism in an elderly female patient with type 2 diabetes mellitus. To determine the probability of sarcopenia in the current study, SARC-F questionnaire was used. Muscle strength was measured using a DMER-120 hand dynamometer. Grip strength was measured using two consecutive measurements on each hand, with the best result selected. Muscle mass was measured using a bioimpedance study followed by calculation of the lean mass index (kg/m2). Muscle strength and mass were assessed at baseline, before semaglutide was prescribed, and after 12 months on the top of already administered therapy. During follow-up examination, we found no negative impact of the selected hypoglycemic therapy, including the incritinomimetic, on the clinical course of geriatric condition.
Keywords
type 2 diabetes mellitus
sarcopenia
hypoglycemic therapy
semaglutide
References
1. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. (Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MА. Epidemiological characteristics of diabetes mellitus in the Russian Federation: Clinical and statistical analysis according to the Federal Diabetes Register data of 01.01.2021. Sakharnyy diabet = Diabetes Mellitus. 2021;24(3):204–221 (In Russ.)).
EDN: MEZKMG. https://doi.org/10.14341/DM12759
2. Инновации в управлении сахарным диабетом 2 типа: сочетание технического прогресса и персонализированного подхода. Эффективная фармакотерапия. 2024;20(29):44–51. (Innovations in the management of type 2 diabetes mellitus: A combination of technological progress and a personalized approach. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2024;20(29):44–51 (In Russ.)). EDN: OSEYKZ.
3. Бернс С.А., Шептулина А.Ф., Мамутова Э.М., Киселев А.Р., Драпкина О.М. Саркопеническое ожирение: эпидемиология, патогенез и особенности диагностики. Кардиоваскулярная терапия и профилактика. 2023;22(6):78–85. (Berns SA, Sheptulina AF, Mamutova EM, Kiselev AR, Drapkina OM. Sarcopenic obesity: Epidemiology, pathogenesis and diagnostic criteria. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(6):78–85 (In Russ.)).
EDN: OWOAYO. https://doi.org/10.15829/1728-8800-2023-3576
4. Sugimoto K, Tabara Y, Ikegami H, Takata Y, Kamide K, Ikezoe T et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low musckle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus. J Diabetes Investig 2019;10(6):1471–79.
PMID: 31074209. PMCID: PMC6825926. https://doi.org/10.1111/jdi.13070
5. Онучина Ю.С., Гурьева И.В. Взаимосвязь саркопении и сахарного диабета типа 2. Эндокринология. Новости. Мнения. Обучение. 2018;7(4):32–41. (Onuchina YuS, Gurieva IV. Association of sarcopenia and type 2 diabetes mellitus. Endokrinologiya. Novosti. Mneniya. Obucheniye = Endocrinology. News, Opinions, Training. 2018;7(4):32–41 (In Russ.)).
EDN: YUEHGH. https://doi.org/10.24411/2304-9529-2018-14004
6. Kamiya M., Kimura N, Umezawa N, Hasgawa H, Yasuda S. Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy. Front Immunol. 2023;14:1191815.
PMID: 37483632. PMCID: PMC10361824. https://doi.org/10.3389/fimmu.2023.1191815
7. Deng F, Wu W, Fan X, Zhong X, Wang N, Wang Y et al. Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. Int J Endocrinol. 2023;2023:9926462.
PMID: 37584041. PMCID: PMC10425251. https://doi.org/10.1155/2023/9926462
8. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
PMID: 30312372. PMCID: PMC6322506. https://doi.org/10.1093/ageing/afy169
9. Мокрышева Н.Г., Крупинова Ю.А, Володичева В.Л., Мирная С.С., Мельниченко Г.А. Саркопения глазами эндокринолога. Ожирение и метаболизм. 2018;15(3):21–27. (Mokrysheva NG, Krupinova JuA, Volodicheva VL, Mirnaya SS, Melnichenko GA. A view at sarcopenia by endocrinologist. Ozhirenie i metabolizm = Obesity and Metabolism. 2018;15(3):21–27 (In Russ.)).
EDN: YOCABF. https://doi.org/10.14341/omet9792
10. Голоунина О.О., Фадеев В.В., Белая Ж.Е. Современные рекомендации по диагностике саркопении. Клиническая медицина. 2023;101(4–5):198–207. (Golounina OO, Fadeev VV, Belaya ZhE. Modern guidelines for the diagnosis of sarcopenia. Klinicheskaya praktika = Journal of Clinical Practice. 2023;101(4–5):198–207 (In Russ.)).
EDN: JFCIHL. https://doi.org/10.30629/0023-2149-2023-101-4-5-198-207
11. Carnevale V, Castriotta V, Piscitelli PA, Nieddu L, Mattera M, Guglielmi G, Scillitani A. Assessment of skeletal muscle mass in older people: Comparison between 2 anthropometry-based methods and dual-energy X-ray absorptiometry. J Am Med Dir Assoc. 2018;19(9):793–96.
PMID: 29983360. https://doi.org/10.1016/j.jamda.2018.05.016
12. Зуйкова А.А., Шевцова В.И., Шевцов А.Н., Кургузова А.С. Саркопеническое ожирение у коморбидных пациентов. Клиническая практика. 2022;13(4):60–67. (Zuikova AA, Shevcova VI, Shevcov AN, Kurguzova AS. Sarcopenic obesity in comorbid patients. Klinicheskaya praktika = Journal of Clinical Practice. 2022;13(4):60–67 (In Russ.)).
EDN: FTSZDY. https://doi.org/10.17816/clinpract112438
13. Goto Y, Otsuka Y, Ashida K, Nagayama A, Hasuzawa N, Iwata S et al. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use. Endocr Connect. 2020;9(7):599–606.
PMID: 32580152. PMCID: PMC7354734. https://doi.org/10.1530/EC-20-0082
14. Massimo E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: Current evidence and underlying machanisms. Cells. 2021;10(8):1958.
PMID: 34440727. PMCID: PMC8393336. https://doi.org/10.3390/cells10081958
15. Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Muracami M, Minami I et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int. 2017;101(1):1–8.
PMID: 28246927. PMCID: PMC5486921. https://doi.org/10.1007/s00223-017-0251-x
About the Authors
Ekaterina V. Uzhakova, MD, PhD (Medicine), associate professor of the Department of endocrinology and clinical pharmacology, Academician E.A. Wagner Perm State Medical University, Perm, Russian Federation.E-mail: uzkaty@mail.ru
ORCID: https://orcid.org/0000-0001-5262-9378
Similar Articles
